All GLG News Analyses Filed Under: Business of Medicine

I believe insurers and pharmacy benefit management companies will coverage of Vytorin.  Most likely, it will lose any preferred status, (formulary Tier 2), and move to non-preferred brand, (formulary Tier 3 or Tier 4), depending on the drug reimbursement system in the health plan.  As an example,...

As a partner @ a VC fund I  see this trend impacting how potential portfolio companies are evaluated.  Companies that will have a future acquisition, as an liquidity event, will have a higher probability of being funded.  Investment decisons are also being influenced by the potential...

According to IMS, independent pharmacies were the fastest growing pharmacy channel in 2007.  In fact, independents grew more than 5 times as fast as chains.  This growth is surprising given the heated rhetoric around the “debilitating consequences” of Part D, Wal-Mart’s “predatory pricing,”...

If I may, Mr. Goldstein suggests that education to providers re: cost/benefit or value will drive drug selection.  I disagree in that there are may barriers to provider (most physicians) behavior and their selection of drugs.  To mention a few are as follows:  1. My anecdotal experience...

The pharmaceutical industry continues to lay its collective head on the chopping block by pushing drugs like Vytorin that demonstrate at best marginal activity. Insurers have a fiduciary duty to push back against the poor judgement of drugmakers who take advantage of confusion and DTC advertising to...

From the rather strick interpretration of Peter Stark's antitrust principles complied with mostly in the 1980's we have entered an era where rampent greed and highly sophisticated antitrust relationships exists in nearly of all hospitals especially with their own "dedicated" (read as owned)  multispecialty...

Illegal and unethical bribes to orthopedists have gone on since time immemorial and have been visible throughout the medical and device profession and business.  Yet little (despite Peter Robert Stark's attempt) to separate this added incentive from the most highly paid specialists in medicine,...

The DOJ joins in when they have reviewed materials and believe it likely that there is a case with some civil or criminal violations.

For one reason, this industry has outperformed the commercial average for the most recent eight years. Secondly, demographics are driving medical services. More of the population is aging. People are living longer. And Medical technology is improving at a rate that provides new and better healthcare...

There are barriers to pharma companies in emerging markets, but if the companies want to make a few bucks, they do not have a choice.